CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
+0.09 (2.43%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.67 - 3.84
52 week 2.45 - 4.65
Open 3.76
Vol / Avg. 832,716.00/517,834.00
Mkt cap 167.25M
P/E     -
Div/yield     -
EPS -1.03
Shares 62.98M
Beta 0.50
Inst. own 31%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -703.75% -92.24%
Operating margin -690.15% -85.64%
EBITD margin - -84.19%
Return on average assets -63.38% -50.91%
Return on average equity -125.46% -159.17%
Employees 100 -
CDP Score - -


3101 Western Ave Ste 800
SEATTLE, WA 98121-3017
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.